GLP-3 R (GLP-1 | GIP | Glucagon) CERTIFICATES OF ANALYSIS 33 COAs BN-26RT50-001 Current Variant: Size: 50mg Retatrutide 49.48 mg / 50.41 mg Purity 99.922% / 99.912% BN-26RT36-001 Current Variant: Size: 36mg Retatrutide 38.97 mg / 39.13 mg Purity 99.614% / 99.686% BN-26RT20-003 Current Variant: Size: 20mg Retatrutide 19.1 mg / 19.83 mg Purity 99.868% / 99.886% BN-26RT15-001 Current Variant: Size: 15mg Retatrutide 14.53 mg / 16.08 mg Purity 99.859% / 99.838% BN-26RT10-003 Current Variant: Size: 10mg Retatrutide 11.33 mg / 10.79 mg Purity 99.630% / 99.739% BN-26RT05-002 Current Variant: Size: 5mg Retatrutide 5.02 mg / 4.95 mg Purity 99.561% / 99.591% BN-25RT60-002 Current Variant: Size: 60mg Retatrutide 60.35 mg Purity 99.891% BN-25RT15-002 Upcoming Variant: Size: 15mg Retatrutide 17.48 mg Purity 99.261% BN-26RT20-002 Previous Variant: Size: 20mg BN-26RT20-001 Previous Variant: Size: 20mg BN-26RT10-002 Previous Variant: Size: 10mg BN-26RT10-001 Previous Variant: Size: 10mg BN-26RT05-001 Previous Variant: Size: 5mg BN-25RT60 Previous Variant: Size: 60mg BN-25RT50-002 Previous Variant: Size: 50mg BN-25RT48-001 Previous Variant: Size: 48mg BN-25RT36-002 Previous Variant: Size: 36mg BN-25RT36-001 Previous Variant: Size: 36mg BN-25RT20-006 Previous Variant: Size: 20mg BN-25RT20-005 Previous Variant: Size: 20mg BN-25RT15-003 Previous Variant: Size: 15mg BN-25RT15-001 Previous Variant: Size: 15mg BN-25RT15-001 Previous Variant: Size: 15mg BN-25RT10-006 Previous Variant: Size: 10mg BN-25RT10-004 Previous Variant: Size: 10mg BN-25RT10-003 Previous Variant: Size: 10mg BN-25RT10-002 Previous Variant: Size: 10mg BN-25RT10-001 Previous Variant: Size: 10mg BN-25RT05-003 Previous Variant: Size: 5mg BN-25RT05-003 Previous Variant: Size: 5mg BN-25RT05-002 Previous Variant: Size: 5mg BN-25RT05-002 Previous Variant: Size: 5mg BN-25RT05-001 Previous Variant: Size: 5mg Small-Batch Research Confidence Focused research supply, documented batch by batch
In addition to reductions in body weight, abdominal fat and liver fat, retatrutide treatment was associated with improvements in insulin sensitivity, lipid metabolism and adipocyte hormones
Stay Upright After Eating Try to sit or walk gently for at least 30 minutes after meals
Clinical trial data from Eli Lillys Phase 2 study showed that the 12mg weekly dose produced an average weight loss of 24.2% over 48 weeks, with over 80% of participants losing at least 15% of their starting body weight
The short answer is that many people begin noticing changes in appetite and food cravings within the first one to four weeks
Focus on technique first, efficiency second
